1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > QUANTUM GENOMICS Corp. - Product Pipeline Review - 2014

QUANTUM GENOMICS Corp. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 23 pages

QUANTUM GENOMICS Corp. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘QUANTUM GENOMICS Corp. - Product Pipeline Review - 2014’, provides an overview of the QUANTUM GENOMICS Corp.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of QUANTUM GENOMICS Corp.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of QUANTUM GENOMICS Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of QUANTUM GENOMICS Corp.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the QUANTUM GENOMICS Corp.’s pipeline products

Reasons to buy

- Evaluate QUANTUM GENOMICS Corp.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of QUANTUM GENOMICS Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the QUANTUM GENOMICS Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of QUANTUM GENOMICS Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of QUANTUM GENOMICS Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of QUANTUM GENOMICS Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

QUANTUM GENOMICS Corp. - Product Pipeline Review - 2014
Table of Contents

QUANTUM GENOMICS Corp. Snapshot 4
QUANTUM GENOMICS Corp. Overview 4
Key Information 4
Key Facts 4
QUANTUM GENOMICS Corp.- Research and Development Overview 5
Key Therapeutic Areas 5
QUANTUM GENOMICS Corp.- Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products- Monotherapy 8
QUANTUM GENOMICS Corp.- Pipeline Products Glance 9
QUANTUM GENOMICS Corp.- Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
QUANTUM GENOMICS Corp.- Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
QUANTUM GENOMICS Corp.- Drug Profiles 12
QGC-001 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
QGC-011 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
QGC-101 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
QGC-006 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
QUANTUM GENOMICS Corp.- Pipeline Products by Route of Administration 17
QUANTUM GENOMICS Corp.- Pipeline Products by Molecule Type 18
QUANTUM GENOMICS Corp.- Recent Pipeline Updates 19
QUANTUM GENOMICS Corp.- Dormant Projects 20
QUANTUM GENOMICS Corp.- Locations And Subsidiaries 21
Head Office 21
Other Locations and Subsidiaries 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23

List of Tables

QUANTUM GENOMICS Corp., Key Information 4
QUANTUM GENOMICS Corp., Key Facts 4
QUANTUM GENOMICS Corp.- Pipeline by Indication, 2014 6
QUANTUM GENOMICS Corp.- Pipeline by Stage of Development, 2014 7
QUANTUM GENOMICS Corp.- Monotherapy Products in Pipeline, 2014 8
QUANTUM GENOMICS Corp.- Phase II, 2014 9
QUANTUM GENOMICS Corp.- Preclinical, 2014 10
QUANTUM GENOMICS Corp.- Discovery, 2014 11
QUANTUM GENOMICS Corp.- Pipeline by Route of Administration, 2014 17
QUANTUM GENOMICS Corp.- Pipeline by Molecule Type, 2014 18
QUANTUM GENOMICS Corp.- Recent Pipeline Updates, 2014 19
QUANTUM GENOMICS Corp.- Dormant Developmental Projects,2014 20
QUANTUM GENOMICS Corp., Subsidiaries 21

List of Figures

QUANTUM GENOMICS Corp. - Pipeline by Top 10 Indication, 2014 6
QUANTUM GENOMICS Corp. - Pipeline by Stage of Development, 2014 7
QUANTUM GENOMICS Corp. - Monotherapy Products in Pipeline, 2014 8

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.